SK51297A3 - Compositions and treatment for multiple sclerosis - Google Patents

Compositions and treatment for multiple sclerosis Download PDF

Info

Publication number
SK51297A3
SK51297A3 SK512-97A SK51297A SK51297A3 SK 51297 A3 SK51297 A3 SK 51297A3 SK 51297 A SK51297 A SK 51297A SK 51297 A3 SK51297 A3 SK 51297A3
Authority
SK
Slovakia
Prior art keywords
seq
mbp
peptide
group
multiple sclerosis
Prior art date
Application number
SK512-97A
Other languages
English (en)
Slovak (sk)
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of SK51297A3 publication Critical patent/SK51297A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK512-97A 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis SK51297A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (fr) 1994-10-25 1995-10-25 Compositions et traitement pour la sclerose en plaques

Publications (1)

Publication Number Publication Date
SK51297A3 true SK51297A3 (en) 1998-03-04

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
SK512-97A SK51297A3 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Country Status (15)

Country Link
EP (1) EP0787147A1 (fr)
JP (1) JPH10504039A (fr)
AU (1) AU4278296A (fr)
BR (1) BR9509438A (fr)
CA (1) CA2203629A1 (fr)
CZ (1) CZ122697A3 (fr)
FI (1) FI971750A (fr)
HU (1) HUT77047A (fr)
IL (1) IL115766A0 (fr)
IS (1) IS4466A (fr)
NO (1) NO971900L (fr)
PL (1) PL324091A1 (fr)
SI (1) SI9520118A (fr)
SK (1) SK51297A3 (fr)
WO (1) WO1996012737A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US6737406B1 (en) 1996-03-21 2004-05-18 Circassia, Ltd. Cryptic peptides and method for their identification
AU3825497A (en) * 1996-08-15 1998-03-06 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (fr) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Specificite des peptides de la proteine basique anti-myeline et administration de ces peptides aux patients atteints de sclerose en plaques
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
WO1999057241A2 (fr) * 1998-05-05 1999-11-11 Corixa Corporation Peptides de proteine basique de myeline et utilisations de ceux-ci
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (fr) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Lymphocytes t actives, antigenes specifiques du systeme nerveux et leur utilisation
EP1288226A1 (fr) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification de l'expression des gènes pour les récepteurs type "Toll" destinée à influencer la neurodégénérescence et la neuroprotection de système nerveux central de l'homme
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
EP1490490B1 (fr) 2002-03-27 2009-05-13 Aegera Therapeutics Inc. Oligomeres nucleobases d'iap antisens et leurs utilisations
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
EP2572734B1 (fr) 2006-10-31 2016-04-06 East Carolina University Protéines de fusion à base de cytokine pour le traitement des troubles immunitaires
EP2328908A4 (fr) * 2008-08-28 2012-11-28 Univ New York State Res Found Traitement des amyloïdoses au moyen de protéines basiques de myéline ou de fragments desdites
EP3348275A3 (fr) * 2009-03-31 2018-10-24 East Carolina University Cytokines et neuroantigènes utilisés dans le traitement de troubles immunitaires
KR20120103591A (ko) 2009-10-12 2012-09-19 라이프바이오 라보라토리즈 엘엘씨 다발성 경화증 치료용 조성물
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
EP2688904B1 (fr) 2011-03-21 2017-12-27 Atlantic Cancer Research Institute Polypeptides présentant une affinité pour les protéines de choc thermique (hsp) et complexes associés à une hsp (hacs) et leur utilisation en diagnostic et en thérapie
US10188708B2 (en) 2014-01-13 2019-01-29 Berg Llc Enolase 1 (Eno1) compositions and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512796B2 (ja) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
BR9007950A (pt) * 1989-12-20 1992-10-27 Brigham & Womens Hospital Metodo para tratamento ou prevencao da manifestacao de uma doenca auto-imune em um mamifero,formulacao farmaceutica,metodo para tratamento de uma doenca auto-imune,e metodo para tratamento de um mamifero acometido de doenca auto-imune
ATE157257T1 (de) * 1990-03-02 1997-09-15 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
CA2053799C (fr) * 1991-10-22 2002-03-12 Kenneth G. Warren Specificite pour les peptides synthetiques de la proteine basique anti-myeline presente dans le liquide cephalorachidien de patients atteints de la sclerose en plaques
EP0661996A4 (fr) * 1991-11-19 1997-05-21 Anergen Inc Conjugues d'une subunite du complexe majeur d'histocompatibilite utiles pour ameliorer les reponses immunitaires deleteres.
KR950700082A (ko) * 1992-02-28 1995-01-16 로버트 씨. 비숍 바이스탠더(bystander)에 의한 자가면역질환을 처치하는 방법
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
ES2172044T3 (es) * 1992-04-09 2002-09-16 Autoimmune Inc Supresion de la proliferacion de celulas t usando fragmentos peptidicos de proteina basica de mielina.
WO1993025661A1 (fr) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Clones heterogenes de cellules t specifiques contre le peptide proteolipidique 139-151
JPH08500823A (ja) * 1992-08-17 1996-01-30 オートイミューン インク レトロウィルス関連神経疾患のバイスタンダー抑制
AU7725894A (en) * 1993-09-03 1995-03-22 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (fr) * 1993-09-06 1995-03-16 La Trobe University Traitement de maladies auto-immunes
AU695801B2 (en) * 1993-09-22 1998-08-20 Board Of Trustees Of The Leland Stanford Junior University Interaction of T-cell receptors and antigen in autoimmune disease
WO1995027500A1 (fr) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TRAITEMENT DE MALADIES AUTO-IMMUNES AVEC DES AGENTS D'INDUCTION DE TOLERANCE ET/OU DES CYTOKINES DE RENFORCEMENT DES Th2 ADMINISTRES PAR VOIE ORALE
BR9507451A (pt) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo
CA2189990A1 (fr) * 1994-05-10 1995-11-16 Di-Hwei Hsu Compositions et traitement de la sclerose en plaques
DK0764273T3 (da) * 1994-06-09 1999-06-23 Tno Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
ATE213499T1 (de) * 1994-11-18 2002-03-15 Neurocrine Biosciences Inc Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose

Also Published As

Publication number Publication date
WO1996012737A2 (fr) 1996-05-02
IL115766A0 (en) 1996-01-19
AU4278296A (en) 1996-05-15
JPH10504039A (ja) 1998-04-14
IS4466A (is) 1997-04-17
BR9509438A (pt) 1997-12-23
WO1996012737A3 (fr) 1996-10-10
NO971900D0 (no) 1997-04-24
CA2203629A1 (fr) 1996-05-02
FI971750A0 (fi) 1997-04-24
EP0787147A1 (fr) 1997-08-06
HUT77047A (hu) 1998-03-02
CZ122697A3 (en) 1997-09-17
FI971750A (fi) 1997-06-24
SI9520118A (sl) 1998-08-31
PL324091A1 (en) 1998-05-11
NO971900L (no) 1997-06-25

Similar Documents

Publication Publication Date Title
SK51297A3 (en) Compositions and treatment for multiple sclerosis
US5858980A (en) Peptide fragments of myelin basic protein
US8343500B2 (en) Peptide composition
Sakai et al. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins.
WO1996012737A9 (fr) Compositions et traitement pour la sclerose en plaques
JP3434510B2 (ja) ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制
JP2009185057A (ja) 自己免疫患を抑制するためのコポリマー、及びその使用方法
IL194987A (en) Use of PIF peptide to produce a drug to regulate the immune system
JP3554319B2 (ja) ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
KR101570383B1 (ko) 조성물
JP2607751B2 (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
JPH09502346A (ja) 自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用
JP2004532896A (ja) Ｉ型糖尿病の診断及び治療
US6355617B1 (en) Peptide derivatives
US20030220229A1 (en) Proinsulin peptide compounds for detecting and treating type I diabetes
WO1996020950A2 (fr) Compositions et therapies pour le traitement de la polyarthrite rhumatoide
US7078044B2 (en) Anti-amoebic vaccine
US20040002113A1 (en) Detection and treatment methods for type I diabetes
US20030176351A1 (en) Peptides and peptide analogues designed from a diabetes-associated autoantigen, and methods for their use in the treatment and prevention of diabetes
AU738564B2 (en) Proinsulin peptide compounds for detecting and treating type I diabetes
WO2020072992A1 (fr) Polypeptides recombinants comprenant des domaines drα1 de classe ii du cmh modifiés et procédés d'utilisation
US20040038920A1 (en) Chlamydial peptides and their mimics in demyelinating disease
AU9724801A (en) Proinsulin peptide compounds for detecting and treating type I diabetes